AnPac Bio-Medical Stock Moves Higher On First Disease Treatment US Patent

• AnPac Bio-Medical Science Co Ltd (NASDAQ: ANPC) has received its first disease treatment patent by the United States Patent and Trademark Office.

• The patent covers novel medical devices for both disease detection and treatment applications and has 25 claims.

• The patent covers novel device structures and methods to modify biological samples for treatment purposes. This latest patent is the 21st patent granted to AnPac Bio in the U.S.

• The Company also announced that its newly launched cancer treatment joint venture has secured, via signed legal documents, over $4 million of capital contributions from multiple funding sources.

• The funding will be used to fabricate cancer treatment medical devices and the device's subsequent laboratory tests this year.

• Price Action: ANPC shares are up 21.9% at $5.29 during the premarket trading session on the last check Friday.

See more from Benzinga

• Click here for options trades from Benzinga

• Registration Statement Related To Cleveland BioLabs-Cytocom Merger Declared Effective By SEC

• Codexis Raises 2021 Revenue Outlook After New Order For Its Enzyme Product

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.